Penzberg, Germany

Ariuna Bazarsuren


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2007-2013

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ariuna Bazarsuren: Innovator in Fusion Polypeptide Technology

Introduction

Ariuna Bazarsuren is a prominent inventor based in Penzberg, Germany. She has made significant contributions to the field of biotechnology, particularly in the area of fusion polypeptides. With a total of 2 patents, her work has advanced the understanding and application of recombinant protein expression.

Latest Patents

Ariuna's latest patents include innovative methods for producing fusion polypeptides and enhancing their expression. The first patent focuses on the cloning and expression of foreign proteins or polypeptides in bacteria. This invention emphasizes the use of expression tools that comprise FKBP-type peptidyl prolyl isomerases, such as FkpA, SlyD, and trigger factor. The methods outlined in this patent facilitate recombinant protein expression and the utilization of the resulting polypeptides. The second patent also addresses the cloning and expression of foreign proteins, highlighting the same FKBP-type isomerases and their applications in producing fusion polypeptides, vaccines, and compositions.

Career Highlights

Ariuna Bazarsuren is currently employed at Roche Diagnostics Operations, Inc., where she continues to innovate in her field. Her work at Roche has allowed her to collaborate with leading experts and contribute to groundbreaking research in biotechnology.

Collaborations

Ariuna has worked alongside notable colleagues, including Christian Scholz and Herbert Andres. These collaborations have further enriched her research and development efforts in the realm of fusion polypeptides.

Conclusion

Ariuna Bazarsuren is a trailblazer in the field of biotechnology, with her patents paving the way for advancements in recombinant protein expression. Her contributions are vital to the ongoing evolution of fusion polypeptide technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…